Fermi surface instabilities at finite Temperature

We present a new method to detect Fermi surface instabilities for interacting systems at finite temperature. We first apply it to a list of cases studied previously, recovering already known results in a very economic way, and obtaining most of the information on the phase diagram analytically. As an example, in the continuum limit we obtain the critical temperature as an implicit function of the magnetic field and the chemical potential $T_c(\mu,h)$. By applying the method to a model proposed to describe reentrant behavior in $Sr_3Ru_2O_7$, we reproduce the phase diagram obtained experimentally and show the presence of a non-Fermi Liquid region at temperatures above the nematic phase.Comment: 10 pages, 10 figure

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium–glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication

The spiritual organization: critical reflections on the instrumentality of workplace spirituality

Authors' draft of article. Final version published by Routledge in Journal of Management, Spirituality and Religion available online at: http://www.tandf.co.uk/journals/titles/14766086.aspThis paper offers a theoretical contribution to the current debate on workplace spirituality by: (a) providing a selective critical review of scholarship, research and corporate practices which treat workplace spirituality in performative terms, that is, as a resource or means to be manipulated instrumentally and appropriated for economic ends; (b) extending Ezioni’s analysis of complex organizations and proposing a new category, the ‘spiritual organization’, and; (c) positing three alternative positions with respect to workplace spirituality that follow from the preceding critique. The spiritual organization can be taken to represent the development of a trajectory of social technologies that have sought, incrementally, to control the bodies, minds, emotions and souls of employees. Alternatively, it might be employed to conceptualize the way in which employees use the workplace as a site for pursuing their own spiritualities (a reverse instrumentalism). Finally, we consider the possible incommensurability of ‘work organization’ and ‘spirituality’ discourses

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

Aims The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether aliskiren, a direct renin inhibitor, would improve post-discharge outcomes in patients with hospitalization for heart failure (HHF) with reduced ejection fraction. Pre-specified subgroup analyses suggested potential heterogeneity in post-discharge outcomes with aliskiren in patients with and without baseline diabetes mellitus (DM). Methods and results ASTRONAUT included 953 patients without DM (aliskiren 489; placebo 464) and 662 patients with DM (aliskiren 319; placebo 343) (as reported by study investigators). Study endpoints included the first occurrence of cardiovascular death or HHF within 6 and 12 months, all-cause death within 6 and 12 months, and change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 1, 6, and 12 months. Data regarding risk of hyperkalaemia, renal impairment, and hypotension, and changes in additional serum biomarkers were collected. The effect of aliskiren on cardiovascular death or HHF within 6 months (primary endpoint) did not significantly differ by baseline DM status (P = 0.08 for interaction), but reached statistical significance at 12 months (non-DM: HR: 0.80, 95% CI: 0.64-0.99; DM: HR: 1.16, 95% CI: 0.91-1.47; P = 0.03 for interaction). Risk of 12-month all-cause death with aliskiren significantly differed by the presence of baseline DM (non-DM: HR: 0.69, 95% CI: 0.50-0.94; DM: HR: 1.64, 95% CI: 1.15-2.33; P < 0.01 for interaction). Among non-diabetics, aliskiren significantly reduced NT-proBNP through 6 months and plasma troponin I and aldosterone through 12 months, as compared to placebo. Among diabetic patients, aliskiren reduced plasma troponin I and aldosterone relative to placebo through 1 month only. There was a trend towards differing risk of post-baseline potassium ≥6 mmol/L with aliskiren by underlying DM status (non-DM: HR: 1.17, 95% CI: 0.71-1.93; DM: HR: 2.39, 95% CI: 1.30-4.42; P = 0.07 for interaction). Conclusion This pre-specified subgroup analysis from the ASTRONAUT trial generates the hypothesis that the addition of aliskiren to standard HHF therapy in non-diabetic patients is generally well-tolerated and improves post-discharge outcomes and biomarker profiles. In contrast, diabetic patients receiving aliskiren appear to have worse post-discharge outcomes. Future prospective investigations are needed to confirm potential benefits of renin inhibition in a large cohort of HHF patients without D

Molecular dynamics simulation of tetracosane (C24H50) adsorbed on graphite beyond the monolayer: the bilayer and trilayer patches

International audience-

Separating Transparent Layers through Layer Information Exchange

In this paper we present an approach for separating two transparent layers in images and video sequences. Given two initial unknown physical mixtures, I1 and I2 , of real scene layers, L1 and L2 , we seek a layer separation which minimizes the structural correlations across the two layers, at every image point. Such a separation is achieved by transferring local grayscale structure from one image to the other wherever it is highly correlated with the underlying local grayscale structure in the other image, and vice versa. This bi-directional transfer operation, which we call the &quot;layer information exchange&quot;, is performed on diminishing window sizes, from global image windows (i.e., the entire image), down to local image windows, thus detecting similar grayscale structures at varying scales across pixels. We show the applicability of this approach to various real-world scenarios, including image and video transparency separation. In particular, we show that this approach can be used for separating transparent layers in images obtained under di#erent polarizations, as well as for separating complex non-rigid transparent motions in video sequences. These can be done without prior knowledge of the layer mixing model (simple additive, alpha-mated composition with an unknown alpha-map, or other), and under unknown complex temporal changes (e.g., unknown varying lighting conditions)

All - atom Molecular Dynamics simulations of tetracosane (C24H50 ) monolayers adsorbed on graphite

International audienceAll - atom Molecular Dynamics simulations of tetracosane (C24H50 ) monolayers adsorbed on graphit